Clinical Trials Logo

HAE clinical trials

View clinical trials related to HAE.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05121376 Recruiting - Clinical trials for Hereditary Angioedema

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

HAErmony-1
Start date: February 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.